ProCE Banner Activity

Selecting Therapy for Less Common Driver Mutations in Advanced Lung Cancer: ALK, ROS, RET, NTRK, MET

Slideset Download
Download these slides from a live webinar for the most recent data on optimal treatment approaches for patients with NSCLC that are positive for less common driver mutations, including ALK, ROS, RET, NTRK, and MET.

Released: April 11, 2022

Expiration: April 10, 2023

No longer available for credit.

Share

Faculty

Todd M. Bauer

Todd M. Bauer, MD

Senior Investigator, Greco-Hainsworth Centers for Research
Tennessee Oncology, PLLC
Nashville, Tennessee

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Lilly

Novartis Pharmaceuticals Corporation

Turning Point Therapeutics Inc

Faculty Disclosure

Primary Author

Todd M. Bauer, MD

Senior Investigator, Greco-Hainsworth Centers for Research
Tennessee Oncology, PLLC
Nashville, Tennessee